BCIP Life Sciences Associates, LP

Track

Insider profile

BCIP Life Sciences Associates, LP's trades of NewAmsterdam Pharma Company NV's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Nuvalent Inc (NUVL)
Transaction date
Proposed sale
Price
43.73
Quantity 18,694
Value US$3,836,110
US Nuvalent Inc (NUVL)
Transaction date
Proposed sale
Price
230.89
Quantity 75,031
Value US$760,315
Transaction date
Proposed sale
Price
13.81
Quantity 38,113
Value US$526,341
Transaction date
Proposed sale
Price
14.73
Quantity 46,428
Value US$683,884
Transaction date
Proposed sale
Price
14.75
Quantity 139,283
Value US$2,054,424
Transaction date
Proposed sale
Price
12.56
Quantity 46,428
Value US$583,136
Transaction date
Proposed sale
Price
11.13
Quantity 92,855
Value US$1,033,476
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-02 2025-12-02
PrS Proposed sale
72,781
30.70
US$26,708 		72,781 30.70 US$26,708
2025-07-24 2025-07-24
US Nuvalent Inc (NUVL)
PrS Proposed sale
18,694
43.73
US$3,836,110 		18,694 43.73 US$3,836,110
2024-12-11 2024-12-11
US Nuvalent Inc (NUVL)
PrS Proposed sale
75,031
230.89
US$760,315 		75,031 230.89 US$760,315
2023-10-24 2023-10-24
PrS Proposed sale
38,113
13.81
US$526,341 		38,113 13.81 US$526,341
2023-10-10 2023-10-10
PrS Proposed sale
46,428
14.73
US$683,884 		46,428 14.73 US$683,884
2023-08-08 2023-08-08
PrS Proposed sale
139,283
14.75
US$2,054,424 		139,283 14.75 US$2,054,424
2023-06-14 2023-06-14
PrS Proposed sale
46,428
12.56
US$583,136 		46,428 12.56 US$583,136
2023-05-18 2023-05-18
PrS Proposed sale
92,855
11.13
US$1,033,476 		92,855 11.13 US$1,033,476